title: Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.
abstract: Tirofiban is a glycoprotein (GP) IIb/IIIa receptor antagonist used in the treatment of acute coronary syndrome (ACS). Thrombocytopenia is a well-known complication of GPIIb/IIIa inhibitors. Life-threatening complications such as alveolar and gastrointestinal system hemorrhages may occur in the course of thrombocytopenia. Platelet count should be monitored closely, including during the first few hours of the infusion. Adverse events may be prevented by prompt discontinuation of the therapy. Herein we present two cases of profound and sudden thrombocytopenia associated with tirofiban use in the treatment of ACS together with a review of the literature.
authors: Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Fatih, 34390 Istanbul, Turkey. o.c.elcioglu@gmail.com
authors: Omer Celal
authors: OC
authors: Elcioglu
authors: Abdullah
authors: A
authors: Ozkok
authors: Timur Selcuk
authors: TS
authors: Akpınar
authors: Fatih
authors: F
authors: Tufan
authors: Murat
authors: M
authors: Sezer
authors: Sabahattin
authors: S
authors: Umman
authors: Sevgi Kalayoglu
authors: SK
authors: Besısık
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications / Q000188:drug therapy; D000368:Aged; D006470:Hemorrhage / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011650:Pulmonary Alveoli / Q000473:pathology*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D000077466:Tirofiban; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban